CL2021002217A1 - Composición farmacéutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda - Google Patents

Composición farmacéutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda

Info

Publication number
CL2021002217A1
CL2021002217A1 CL2021002217A CL2021002217A CL2021002217A1 CL 2021002217 A1 CL2021002217 A1 CL 2021002217A1 CL 2021002217 A CL2021002217 A CL 2021002217A CL 2021002217 A CL2021002217 A CL 2021002217A CL 2021002217 A1 CL2021002217 A1 CL 2021002217A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
myeloid leukemia
acute myeloid
hypomethylating agent
treat acute
Prior art date
Application number
CL2021002217A
Other languages
English (en)
Spanish (es)
Inventor
Jae Yul Choi
In Hwan Bae
Ji Sook Kim
Young Gil Ahn
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200021502A external-priority patent/KR20200102949A/ko
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2021002217A1 publication Critical patent/CL2021002217A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2021002217A 2019-02-22 2021-08-19 Composición farmacéutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda CL2021002217A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190021228 2019-02-22
KR1020200021502A KR20200102949A (ko) 2019-02-22 2020-02-21 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물

Publications (1)

Publication Number Publication Date
CL2021002217A1 true CL2021002217A1 (es) 2022-04-29

Family

ID=72144358

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002217A CL2021002217A1 (es) 2019-02-22 2021-08-19 Composición farmacéutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda

Country Status (8)

Country Link
US (1) US12433867B2 (cg-RX-API-DMAC7.html)
JP (1) JP7577672B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016522A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002217A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021010115A (cg-RX-API-DMAC7.html)
PE (1) PE20212153A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551985A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020171646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EP3991733A4 (en) * 2019-06-27 2023-07-05 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
KR20230056331A (ko) * 2021-10-20 2023-04-27 한미약품 주식회사 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
EP4525873A1 (en) 2022-05-17 2025-03-26 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
KR20090087094A (ko) 2006-11-28 2009-08-14 노파르티스 아게 Iap 억제제 및 flt3 억제제의 조합물
JPWO2008111441A1 (ja) 2007-03-05 2010-06-24 協和発酵キリン株式会社 医薬組成物
CA2702126A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
TW201022262A (en) 2008-10-29 2010-06-16 Astrazeneca Ab Novel compounds 515
CN102438588B (zh) 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
ES2622138T3 (es) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
DK3686193T3 (da) 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
WO2014155300A2 (en) 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
MX358346B (es) 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
CA2949793C (en) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN113121575A (zh) 2014-08-25 2021-07-16 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
JP6564449B2 (ja) 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
WO2016155655A1 (zh) 2015-04-03 2016-10-06 上海瑛派药业有限公司 Parp抑制剂固体药物剂型及其应用
KR101799781B1 (ko) 2015-07-23 2017-11-22 재단법인 강릉과학산업진흥원 소뼈 추출분말의 제조방법
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN107531725B (zh) 2015-08-13 2021-03-19 北京韩美药品有限公司 Irak4抑制剂及其应用
CA2998042C (en) 2015-09-14 2022-07-05 Brunangelo Falini Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
BR112018009463A8 (pt) 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
EP3436014A4 (en) * 2016-03-29 2019-11-27 Astellas Pharma Inc. COMBINATION THERAPY FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA
EP3478675B1 (en) 2016-06-30 2020-04-22 Janssen Pharmaceutica NV Heteroaromatic derivatives as nik inhibitors
PL3541387T3 (pl) 2016-11-15 2021-10-25 Novartis Ag Dawka i schemat dla inhibitorów interakcji hdm2-p53
MA47233A (fr) 2016-12-19 2019-10-23 Epizyme Inc Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
PE20191108A1 (es) 2017-01-17 2019-08-26 Astrazeneca Ab Inhibidores selectivos de jak1
KR102175710B1 (ko) 2017-01-23 2020-11-06 주식회사 엘지화학 폴리아릴렌 설파이드 수지 조성물
TWI810172B (zh) 2017-01-26 2023-08-01 南韓商韓美藥品股份有限公司 嘧啶化合物及包括其的藥學組成物
KR20190128646A (ko) 2017-02-21 2019-11-18 압토스 바이오사이언시스 인코포레이티드 혈액 종양 환자들의 치료 방법
WO2019025484A1 (en) 2017-08-01 2019-02-07 Julius-Maximilians-Universität Würzburg USE OF CAR-MODIFIED T LYMPHOCYTES FOR FLT3 AND FLT3 INHIBITORS FOR TREATING ACUTE MYELOID LEUKEMIA
CA3080197C (en) 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
KR102297587B1 (ko) 2018-08-07 2021-09-06 재단법인 대구경북첨단의료산업진흥재단 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CN113166110B (zh) 2018-12-12 2023-08-11 暨南大学 2-氨基嘧啶类化合物及其应用
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
EP3928780A4 (en) 2019-02-22 2022-12-07 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA
WO2020171649A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
EP3991733A4 (en) 2019-06-27 2023-07-05 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
WO2021066443A1 (ko) 2019-09-30 2021-04-08 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
WO2021159993A1 (en) 2020-02-14 2021-08-19 Pharmablock Sciences (Nanjing) , Inc. Inhibitors of interleukin-1 receptor associated kinase (irak) /fms-like receptor tyrosine kinase (flt3), pharmaceutical products thereof, and methods thereof
CN116583284A (zh) 2020-11-05 2023-08-11 韩美药品株式会社 用于治疗髓性白血病的包括flt3抑制剂的药物组合物
KR20230056331A (ko) 2021-10-20 2023-04-27 한미약품 주식회사 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
AU2023372170A1 (en) 2022-11-04 2025-04-24 Hanmi Pharm. Co., Ltd. Novel crystalline form of a pyrimidine compound and pharmaceutical compositions comprising the same and methods of use thereof
CN120857931A (zh) 2022-12-10 2025-10-28 艾普托斯生物科学公司 用于治疗患有血液学恶性病的患者的方法
EP4719355A1 (en) 2023-05-31 2026-04-08 Hanmi Pharm. Co., Ltd. Solid dispersion of myeloid kinome inhibitors and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
MX2021010115A (es) 2021-09-21
JP2022521380A (ja) 2022-04-07
BR112021016522A2 (pt) 2021-10-26
JP7577672B2 (ja) 2024-11-05
WO2020171646A1 (ko) 2020-08-27
US20220110913A1 (en) 2022-04-14
US12433867B2 (en) 2025-10-07
PH12021551985A1 (en) 2022-08-22
PE20212153A1 (es) 2021-11-09

Similar Documents

Publication Publication Date Title
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2021015724A (es) Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.
MX2021010115A (es) Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
MX2020007947A (es) Inhibidores de erbb/btk.
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
MX2022012285A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
AR112103A1 (es) Compuestos para el tratamiento de tnbc
AR119158A1 (es) Tratamientos de angioedema hereditario
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
WO2018102687A3 (en) Combination therapy for treating cancer
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
MX2025005474A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
AR121598A1 (es) Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano
EA202191984A1 (ru) Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
PY1944026A (es) Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
AR134429A1 (es) Inhibidores de parg